» Articles » PMID: 30320620

Methylglyoxal Stress, the Glyoxalase System, and Diabetic Chronic Kidney Disease

Overview
Date 2018 Oct 16
PMID 30320620
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose Of Review: Chronic kidney disease (CKD) remains a serious diabetic complication despite the use of widely employed interventions such as angiotensin-converting enzyme inhibitors and glucose-lowering treatments. Accumulation of methylglyoxal, a highly reactive glucose metabolite and a major precursor in the formation of advanced glycation end products, may link the hemodynamic, inflammatory, metabolic, and structural changes that drive diabetic CKD. Therefore, methylglyoxal may serve as a potential therapeutic target to prevent diabetic CKD.

Recent Findings: Higher plasma methylglyoxal levels were shown to be associated with a decline in the estimated glomerular filtration rate. Furthermore, interventions that lower methylglyoxal levels reduced albuminuria in rodent models of diabetes. In addition, the glyoxalase system, which detoxifies methylglyoxal into D-lactate, has been identified as a key protective enzymatic system against diabetic CKD in both human and rodent studies. Recently, several promising treatments to lower methylglyoxal directly or to boost the glyoxalase system have been identified.

Summary: The review highlights the mechanisms through which methylglyoxal is formed in diabetes, and how methylglyoxal contributes to the mechanisms that drive CKD in diabetes. Furthermore, we discuss the role of glyoxalase-1 in diabetic CKD. Finally, we discuss recent data about treatments that lower methylglyoxal stress.

Citing Articles

Sanger Sequencing Reveals Novel Variants in , , and Genes in Patients of Early and Severe Diabetic Nephropathy.

Shah S, Rashid A, Majeed A, Ghafoor T, Azam N Medicina (Kaunas). 2024; 60(9).

PMID: 39336582 PMC: 11433688. DOI: 10.3390/medicina60091540.


Lycopene in Combination with Insulin Triggers Antioxidant Defenses and Increases the Expression of Components That Detoxify Advanced Glycation Products in Kidneys of Diabetic Rats.

Figueiredo I, Lima T, Carlstrom P, Assis R, Brunetti I, Baviera A Nutrients. 2024; 16(11).

PMID: 38892513 PMC: 11173891. DOI: 10.3390/nu16111580.


Methylglyoxal and Advanced Glycation End Products (AGEs): Targets for the Prevention and Treatment of Diabetes-Associated Bladder Dysfunction?.

Oliveira A, de Oliveira M, Monica F, Antunes E Biomedicines. 2024; 12(5).

PMID: 38790901 PMC: 11118115. DOI: 10.3390/biomedicines12050939.


Determination of Glyoxalase-1 levels and Identification of Genetic Variants in Gene in Patients of Diabetic Nephropathy.

Shah S, Rashid A, Majeed A Pak J Med Sci. 2024; 40(4):652-656.

PMID: 38545031 PMC: 10963954. DOI: 10.12669/pjms.40.4.8258.


Protective effects of crocin and gallic acid on the liver damage induced by methylglyoxal in male mice: role of inflammatory factors.

Radmehr V, Mojadami S, Ahangarpour A, Mard S Gastroenterol Hepatol Bed Bench. 2023; 16(1):499-508.

PMID: 37070111 PMC: 10105510. DOI: 10.22037/ghfbb.v16i1.2620.